Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Engage Grants Program

Dalhousie University

$25,000.00

Mechanisms of action studies of WBI-4002, a novel drug candidate promoting epithelial integrity

EF 2019-20

Résumé
The cells lining our tissue surfaces in contact with the environment are called epithelial cells. To create a barrier epithelial cells are tightly connected to each other and are sometimes stacked upon each other, like on our skin. In the intestines the epithelium is only one cell thick in order to digest and absorb food. The result is that the ""tightness"" can be modified by events in the host or from products arriving in the lumen. These changes in ""tightness"" or integrity occur during diseases like Celiac disease or Crohn's disease and ulcerative colitis. While we understand the molecules involved in epithelial integrity we don't have many products that can improve it when we may need to, but we have some clues from our the food. Certain plants in our diet are thought to have anti-inflammatory and anti-oxidant properties (blueberries, for example). As scientists worked to purify the active plant products ""polyphenol stilbenes"" were discovered to have health benefits. Welichem Biotech Inc. (Burnaby, BC) has developed a drug in this class they call WBI-4002. WBI-4002 is a trans-hydroxystilbene. They have learned that the drug binds a molecule on the surface of cells called the aryl hydrocarbon receptor (AhR). The AhR is present on many types of cells including on epithelial cells. Other researchers showed that when the AhR binds compatible molecules it can improve the integrity of the epithelium. Welichem Biotech Inc. wants to know if their drug can also modify the integrity of epithelium. The Company contacted Dr. Stadnyk, who is an expert on the intestinal epithelium. Dr. Stadnyk will apply WBI-4002 to intestinal epithelial cells, from humans and mice, in petri dishes, and measure any effects on integrity. He will examine the molecules that make up the bonds between cells to figure out what changes when WBI0-4002 is applied. If the drug works to improve epithelial integrity it may be a good candidate for treating inflammatory diseases of the intestines.
Programme
Engage Grants Program
Bénéficiaire
Emplacement
Nova Scotia, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data

Tel que publié

Application id
543615-2019
Name nom
Stadnyk, Andrew
Department département
Pediatrics
Organization id
79
Institution établissement
Dalhousie University
Province en
Nova Scotia
Province fr
Nouvelle-Écosse
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2019
Competition year année de concours
2019
Award amount
25000
Program id
EGP
Program name en
Engage Grants Program
Program name fr
Programme de subventions d'engagement partenariat
Group en
RESEARCH PARTNERSHIPS
Group fr
PARTENARIATS DE RECHERCHE
Committee code
1551
Committee name en
Atlantic Internal Decision Committee
Committee name fr
Comité de décision interne pour l'Atlantique
Area of application code
504
Area of application group en
Manufacturing processes and products
Area of application group fr
Procédés et produits industriels
Area of application en
Human pharmaceuticals
Area of application fr
Produits pharmaceutiques administrables à l'homme
Research subject code
5100
Research subject group en
Cell biology
Research subject group fr
Biologie cellulaire
Research subject en
Cell biology
Research subject fr
Biologie cellulaire
Installment
inst:1 - 1
Partie
1
Nb partie
1
Application title
Mechanisms of action studies of WBI-4002, a novel drug candidate promoting epithelial integrity
Keyword
NSERC
Application summary
The cells lining our tissue surfaces in contact with the environment are called epithelial cells. To create a barrier epithelial cells are tightly connected to each other and are sometimes stacked upon each other, like on our skin. In the intestines the epithelium is only one cell thick in order to digest and absorb food. The result is that the ""tightness"" can be modified by events in the host or from products arriving in the lumen. These changes in ""tightness"" or integrity occur during diseases like Celiac disease or Crohn's disease and ulcerative colitis. While we understand the molecules involved in epithelial integrity we don't have many products that can improve it when we may need to, but we have some clues from our the food. Certain plants in our diet are thought to have anti-inflammatory and anti-oxidant properties (blueberries, for example). As scientists worked to purify the active plant products ""polyphenol stilbenes"" were discovered to have health benefits. Welichem Biotech Inc. (Burnaby, BC) has developed a drug in this class they call WBI-4002. WBI-4002 is a trans-hydroxystilbene. They have learned that the drug binds a molecule on the surface of cells called the aryl hydrocarbon receptor (AhR). The AhR is present on many types of cells including on epithelial cells. Other researchers showed that when the AhR binds compatible molecules it can improve the integrity of the epithelium. Welichem Biotech Inc. wants to know if their drug can also modify the integrity of epithelium. The Company contacted Dr. Stadnyk, who is an expert on the intestinal epithelium. Dr. Stadnyk will apply WBI-4002 to intestinal epithelial cells, from humans and mice, in petri dishes, and measure any effects on integrity. He will examine the molecules that make up the bonds between cells to figure out what changes when WBI0-4002 is applied. If the drug works to improve epithelial integrity it may be a good candidate for treating inflammatory diseases of the intestines.